Stock Track | PROCEPT BioRobotics Plunges 5.20% Pre-Market on Disappointing 2026 Revenue Guidance Despite Q3 Beat

Stock Track11-05

Shares of PROCEPT BioRobotics (NASDAQ: PRCT) tumbled 5.20% in pre-market trading on Wednesday, following the release of the company's third-quarter earnings report and 2026 revenue guidance. The surgical robotics company's stock price decline comes despite beating analyst expectations for Q3, as investors appear concerned about the company's future growth trajectory.

PROCEPT BioRobotics reported strong Q3 results, with revenue of $83.3 million surpassing the analyst estimate of $80.9 million. The company's adjusted EBITDA loss of $7.4 million also outperformed expectations, coming in better than the anticipated loss of $10.2 million. However, these positive results were overshadowed by the company's forward-looking projections.

While PROCEPT BioRobotics maintained its fiscal year 2025 revenue guidance of approximately $325.5 million, representing a 45% year-over-year growth, it was the newly issued fiscal year 2026 revenue guidance that disappointed investors. The company projects 2026 revenue to be in the range of $410 million to $430 million, indicating a growth rate of 26% to 32% compared to the 2025 guidance. This potential deceleration in growth appears to be the primary factor behind the stock's sharp pre-market decline, as investors had likely anticipated more aggressive growth projections for the coming year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183806499?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183806499","market":"hk","top_or_hot":-1,"title":"Stock Track | PROCEPT BioRobotics Plunges 5.20% Pre-Market on Disappointing 2026 Revenue Guidance Despite Q3 Beat","media":"Stock Track","content":"<p>Shares of PROCEPT BioRobotics (NASDAQ: PRCT) tumbled 5.20% in pre-market trading on Wednesday, following the release of the company's third-quarter earnings report and 2026 revenue guidance. The surgical robotics company's stock price decline comes despite beating analyst expectations for Q3, as investors appear concerned about the company's future growth trajectory.</p>\n\n<p>PROCEPT BioRobotics reported strong Q3 results, with revenue of $83.3 million surpassing the analyst estimate of $80.9 million. The company's adjusted EBITDA loss of $7.4 million also outperformed expectations, coming in better than the anticipated loss of $10.2 million. However, these positive results were overshadowed by the company's forward-looking projections.</p>\n\n<p>While PROCEPT BioRobotics maintained its fiscal year 2025 revenue guidance of approximately $325.5 million, representing a 45% year-over-year growth, it was the newly issued fiscal year 2026 revenue guidance that disappointed investors. The company projects 2026 revenue to be in the range of $410 million to $430 million, indicating a growth rate of 26% to 32% compared to the 2025 guidance. This potential deceleration in growth appears to be the primary factor behind the stock's sharp pre-market decline, as investors had likely anticipated more aggressive growth projections for the coming year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | PROCEPT BioRobotics Plunges 5.20% Pre-Market on Disappointing 2026 Revenue Guidance Despite Q3 Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | PROCEPT BioRobotics Plunges 5.20% Pre-Market on Disappointing 2026 Revenue Guidance Despite Q3 Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of PROCEPT BioRobotics (NASDAQ: PRCT) tumbled 5.20% in pre-market trading on Wednesday, following the release of the company's third-quarter earnings report and 2026 revenue guidance. The surgical robotics company's stock price decline comes despite beating analyst expectations for Q3, as investors appear concerned about the company's future growth trajectory.</p>\n\n<p>PROCEPT BioRobotics reported strong Q3 results, with revenue of $83.3 million surpassing the analyst estimate of $80.9 million. The company's adjusted EBITDA loss of $7.4 million also outperformed expectations, coming in better than the anticipated loss of $10.2 million. However, these positive results were overshadowed by the company's forward-looking projections.</p>\n\n<p>While PROCEPT BioRobotics maintained its fiscal year 2025 revenue guidance of approximately $325.5 million, representing a 45% year-over-year growth, it was the newly issued fiscal year 2026 revenue guidance that disappointed investors. The company projects 2026 revenue to be in the range of $410 million to $430 million, indicating a growth rate of 26% to 32% compared to the 2025 guidance. This potential deceleration in growth appears to be the primary factor behind the stock's sharp pre-market decline, as investors had likely anticipated more aggressive growth projections for the coming year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRCT","symbol_name":"PROCEPT BioRobotics","start_time":0,"source_url":"","article_id":"1183806499","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183806499","pubTimestamp":1762347833,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of PROCEPT BioRobotics (NASDAQ: PRCT) tumbled 5.20% in pre-market trading on Wednesday, following the release of the company's third-quarter earnings report and 2026 revenue guidance. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"translate_title":"股票追踪|PROCEPT BioRobotics盘前暴跌5.20%，原因是2026年营收指引令人失望，尽管第三季度表现出色","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRCT":1},"content_text":"Shares of PROCEPT BioRobotics (NASDAQ: PRCT) tumbled 5.20% in pre-market trading on Wednesday, following the release of the company's third-quarter earnings report and 2026 revenue guidance. The surgical robotics company's stock price decline comes despite beating analyst expectations for Q3, as investors appear concerned about the company's future growth trajectory.\nPROCEPT BioRobotics reported strong Q3 results, with revenue of $83.3 million surpassing the analyst estimate of $80.9 million. The company's adjusted EBITDA loss of $7.4 million also outperformed expectations, coming in better than the anticipated loss of $10.2 million. However, these positive results were overshadowed by the company's forward-looking projections.\nWhile PROCEPT BioRobotics maintained its fiscal year 2025 revenue guidance of approximately $325.5 million, representing a 45% year-over-year growth, it was the newly issued fiscal year 2026 revenue guidance that disappointed investors. The company projects 2026 revenue to be in the range of $410 million to $430 million, indicating a growth rate of 26% to 32% compared to the 2025 guidance. This potential deceleration in growth appears to be the primary factor behind the stock's sharp pre-market decline, as investors had likely anticipated more aggressive growth projections for the coming year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183806499","isCrawlerRequest":true}